Fred Koehl Shares the Lessons from His Cholangiocarcinoma Diagnosis, Awaiting a Treatment to "Beat This Thing"

August 2020, Vol 1, No 1

Fred Koehl, who spoke at the 2020 Cholangiocarcinoma Foundation (CCF) Annual Conference, was a 62-year-old healthy man living in Atlanta, GA, who was “not ready to go” when he was diagnosed with extrahepatic cholangiocarcinoma (CCA) 7 years ago. Mr Koehl’s disease was diagnosed at an early stage (stage I), and after surgery to remove the tumor (including part of his pancreas), radiation, and 12 cycles of gemcitabine and cisplatin therapy, he was told he had “no evidence of disease.”

That continued until early 2017, when he had a recurrence of CCA. More chemotherapy and a surgical procedure to remove a tumor became Mr Koehl’s new reality. He is currently receiving treatment in a clinical trial, and his best hopes at this stage of his life are disease stability, if not tumor shrinkage, and staying in the clinical trial.

As of the CCF conference, Mr Koehl’s disease is stable, but his CA19-9 level continues to rise, and 2 suspicious areas were noted on a recent scan. “My objective is to keep kicking the can down the road until a treatment is found so that I can beat this thing,” he told the audience.

5 Tips for Patients with CCA

Mr Koehl’s advice to other patients with CCA is meant primarily for men and women who were newly diagnosed with this type of cancer, but it is relevant to all patients with this disease.

“I cannot get rid of your cancer any more than I can get rid of mine, but maybe I can provide some thoughts about how to make the journey a bit less scary, and maybe have you think of some ways to deal with all of this stuff a little better,” Mr Koehl said. He discussed the following 5 major themes that he has used as a guide in his experience with cancer.

  1. Seek knowledge to be empoweredKnow that there are many resources being expended today with the goal of treating and ultimately beating CCA. Knowledge is empowering. Be an informed patient, not a victim.
  2. Explore and act on your optionsGenomic testing is widely available these days. Get tested! Genetic mutations do matter. Some of the best treatment success stories started with genomic testing. Get the best medical team that you can. Push hard to get the best treatment available. The CCF can help with your search. And take good care of yourself. Live your life in the healthiest way possible. Good lifestyle choices can help improve the likelihood of your success in this battle.
  3. Make plans and live your lifeIn many ways, this is easier said than done, but don’t sit back and say, “woe is me.” None of us is promised tomorrow, so have short- and long-term life goals and objectives.
  4. Be physically activePhysical activity can help during cancer treatment and recovery. Don’t let a physical limitation prevent you from maintaining an active lifestyle. Do something every day, and then a little bit more tomorrow.
  5. You are not aloneSupport cannot cure CCA, but it can certainly make your experience better. Knowledge, concern, and care are things that can come from other patients with CCA and our caregivers.

“All of us can gain from the support of one another. Be open to sharing and gaining the benefit of what we all can offer one another,” Mr Koehl concluded.

Related Items

Biomarker Discovery and Early Detection in CCA
June 2025, Vol 6, No 2
Experts unveiled a roadmap for translating cutting-edge biomarkers into clinical practice, paving the way for improved early detection and personalized care in high-risk populations with cholangiocarcinoma (CCA).
Translational Science and Discovery in CCA
June 2025, Vol 6, No 2
Leading experts explored groundbreaking advancements in tumor microenvironments, biomarker validation, and innovative therapies, paving the way for transformative precision medicine in cholangiocarcinoma (CCA) care.
Advancements in Cholangiocarcinoma Diagnosis and Treatment: Radiomics, Biomarkers, and Optimal Biliary Decompression
June 2025, Vol 6, No 2
Cutting-edge advancements in tumor microenvironments, therapeutic resistance, biomarker validation, and innovative treatments are paving the way for breakthroughs in precision medicine.
Pathology in CCA
June 2025, Vol 6, No 2
Experts in cholangiocarcinoma (CCA) have explored the transformative role of artificial intelligence in improving CCA diagnosis, predictive marker identification, and understanding precursor lesions to advance targeted therapies and personalized care.
Locoregional Therapies and Radiation for the Treatment of Patients With CCA
June 2025, Vol 6, No 2
Experts have highlighted the latest advancements in locoregional treatments, including hepatic arterial infusion, selective internal radiation therapy, ablation techniques, and histotripsy, offering new hope for improving survival in cholangiocarcinoma (CCA) patients.
Systemic Therapies and Surgery for CCA
June 2025, Vol 6, No 2
Experts discuss advancements in systemic therapies, surgical strategies, and liver transplantation, offering new hope for improving outcomes in patients with cholangiocarcinoma (CCA).
Tinengotinib: A Next-Generation Fibroblast Growth Factor Receptor (FGFR) Inhibitor for CCA
June 2025, Vol 6, No 2
Tinengotinib emerged as a promising next-generation multikinase inhibitor, offering new hope for patients with resistant cholangiocarcinoma (CCA) through its innovative mechanism of action and encouraging clinical trial results.
Advancing Oncology Research Through Novel Endpoints and Consensus-Driven Collaboration
June 2025, Vol 6, No 2
A collaborative roadmap has been unveiled to redefine clinical endpoints, advance precision medicine, and align global efforts in tackling the challenges of rare and aggressive biliary tract cancers.
AI-Driven Approaches in CCA
June 2024, Vol 5, No 2
Three presentations discussed the application of artificial intelligence learning– and machine learning-driven approaches to improve pathology, radiology, and drug discovery processes, showing strong potential for improving outcomes in patients with cholangiocarcinoma.
Cancer Vaccines Targeting WT1 for CCA
June 2024, Vol 5, No 2
Benjamin L. Green, MD, presented Wilms’ tumor 1 vaccine novel adoptive cell therapy approaches for advanced solid cancers, including the role of immunotherapy in treating advanced cholangiocarcinoma.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Profession or Role
Primary Specialty or Disease State